Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy

Leuk Lymphoma. 2007 May;48(5):1053-6. doi: 10.1080/10428190701258370.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / pathology
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / genetics
  • Central Nervous System Neoplasms / mortality
  • Central Nervous System Neoplasms / pathology*
  • Dasatinib
  • Humans
  • In Situ Hybridization, Fluorescence
  • Inhibitory Concentration 50
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Pyrimidines / therapeutic use*
  • Remission Induction
  • Thiazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Pyrimidines
  • Thiazoles
  • Dasatinib